Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics (NRIX), a biopharmaceutical company, has advanced four clinical programs from its DELigase platform into clinical development. In 2021, significant milestones were achieved, including the demonstration of targeted protein degradation in patients with hematologic malignancies. For 2022, Nurix anticipates data presentations from all four programs, including NX-2127, NX-5948, NX-1607, and DeTIL-0255. Additionally, a public offering raised approximately $150 million, aiding further development. Collaborations with Sanofi and new initiatives in pediatric cancers are also highlighted.
Nurix Therapeutics (Nasdaq: NRIX) announces that Arthur T. Sands, M.D., Ph.D., will present the company's performance and goals at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 5:15 PM ET. The presentation will be available via a live webcast on Nurix's website and archived for 30 days post-event. Nurix focuses on developing targeted protein modulation therapies for cancer, leveraging its DELigase platform and expertise in E3 ligases to create novel drug candidates.
Nurix Therapeutics (NRIX) announced that the U.K. Medicines & Healthcare products Regulatory Agency granted Clinical Trial Authorization (CTA) for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK). The Phase 1 trial for patients with relapsed B-cell malignancies is set to begin in early 2022. Preclinical studies revealed NX-5948’s effectiveness, showing significant tumor reduction and improved survival rates in models. Notably, it crossed the blood-brain barrier, positioning it for dual development in oncology and autoimmune diseases.
Nurix Therapeutics announced FDA clearance for its DeTIL-0255 Investigational New Drug Application, paving the way for a Phase 1 clinical trial expected to begin by year-end 2021. DeTIL-0255 is an autologous T cell therapy targeting advanced malignancies, particularly gynecological cancers. The trial aims to enroll up to 50 patients, focusing on recurrent or persistent cancers. This advancement follows the company's success with its oral CBL-B inhibitor, NX-1607, currently in Phase 1a trials.
Nurix Therapeutics (Nasdaq: NRIX) announced preclinical findings for its CBL-B inhibitor, NX-0255, that enhance T cell expansion and quality for tumor infiltrating lymphocyte (TIL) therapy. Results show DeTIL-0255, a drug-enhanced TIL candidate, generated significant increases in T cell expansion (p<0.001), reduced exhaustion markers (p<0.05), and improved cytotoxicity (p<0.001). The findings support advancing DeTIL-0255 into clinical trials, with plans for a Phase 1 trial targeting patients with gynecological tumors. Additionally, Michael T. Lotze, the company's CCO, received the 2021 SITC Lifetime Achievement Award.
Nurix Therapeutics (Nasdaq: NRIX) has announced that its CEO, Arthur T. Sands, M.D., Ph.D., will participate in two upcoming virtual healthcare conferences in November. The events include the Stifel 2021 Virtual Healthcare Conference on November 16, from 3:20 to 3:50 PM EST, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, from 11:30 to 11:55 AM EST. These discussions will be available via live webcast through the Investors section of the Nurix website, with archived copies accessible for 30 days following each event.
Nurix Therapeutics (NRIX) has reported initial data on its lead drug candidate, NX-2127, demonstrating over 90% degradation of Bruton’s tyrosine kinase (BTK) in patients with relapsed B-cell malignancies. This achievement marks a significant milestone in the targeted protein degradation approach for treating cancers. The phase 1a study reported promising results, with patients showing sustained BTK suppression and a notable partial response in a CLL patient resistant to traditional therapies. The company plans to advance to the expansion phase in 2022.
Nurix Therapeutics (NRIX) is set to present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 for treating relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation occurs on October 27, 2021, at 11:45 a.m. ET, led by CEO Arthur T. Sands. A conference call for further discussion will precede the presentation at 8:30 a.m. ET. NX-2127 is an orally bioavailable degrader of BTK, aimed at addressing treatment resistance in affected patients.
Nurix Therapeutics (Nasdaq: NRIX) announces participation in the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Key sessions include:
- Pre-Conference Workshop on TPD basics by Gwenn M. Hansen, Ph.D. on October 26 at 8:30 a.m. ET.
- Oral Session on clinical updates by CEO Arthur T. Sands, M.D., Ph.D. on October 27 at 11:45 a.m. ET.
- Panel Discussions on therapeutic applications and diversity led by Sands and Hansen on October 27 and 28.
This summit highlights Nurix's commitment to advancing targeted protein modulation for cancer treatment.
Nurix Therapeutics (NRIX) reported its Q3 2021 financial results, highlighting a strong cash position of $465.4 million as of August 31, 2021. The company initiated a Phase 1 trial for its lead E3 ligase inhibitor NX-1607, now with two drug candidates in clinical development. Collaboration revenue rose to $10.3 million, up from $4.1 million year-on-year, driven by collaborations with Sanofi and Gilead. However, R&D expenses increased to $30.9 million, resulting in a net loss of $28.8 million or ($0.65) per share, up from ($1.09) per share a year earlier.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
